Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Youkefei (优克非) is a branded generic formulation of sildenafil citrate developed and manufactured by Yangzijiang Pharmaceutical Group. It is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5), the primary enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum of the penis. By inhibiting PDE5, sildenafil increases the levels of cGMP, which enhances the vasodilatory effects of nitric oxide on penile smooth muscle, leading to increased blood flow and facilitating an erection in response to sexual stimulation. Youkefei is administered orally in tablet form and is approved in China for the treatment of erectile dysfunction (ED).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Youkefei.